Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Migraine

Free Subscription Articles published in Cephalalgia Retrieve available abstracts of 275 articles: HTML format

Single Articles

December 2025
1. GRECO R, Bighiani F, Demartini C, Zanaboni A, et al
   miR-382-5p and miR-34a in migraine: Expression in monocytes and a post-hoc exploratory comparison with expression in peripheral blood mononuclear cells.
   Cephalalgia. 2025;45:3331024251386769.
   PubMed     Abstract available
   
   
   
2. IANNONE LF, Romozzi M, Russo A, Finkelstein I, et al
   Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study).
   Cephalalgia. 2025;45:3331024251398011.
   PubMed     Abstract available
   
   
   
3. ATRASZKIEWICZ D, Unal E, Bassett P, Morell-Ducos F, et al
   Greater occipital nerve block for the treatment of migraine: An umbrella review, systematic review, and meta-analysis.
   Cephalalgia. 2025;45:3331024251398390.
   PubMed     Abstract available
   
   
   November 2025
4. TFELT-HANSEN P, Hougaard A
   Some observed problems of the evidence presented for zolmitriptan nasal spray in the "Evidence-Based Recommendations of Pharmacological Treatment of Migraine Attacks".
   Cephalalgia. 2025;45:3331024251393937.
   PubMed    
   
   
   
5. ORNELLO R, Russo A, Orologio I, Silvestro M, et al
   Response to the Letter by Tfelt-Hansen and Hougaard "Some observed problems of the evidence presented for zolmitriptan nasal spray in the "Evidence-Based Recommendations of Pharmacological Treatment of Migraine Attacks".
   Cephalalgia. 2025;45:3331024251393936.
   PubMed    
   
   
   
6. LOOSE L, Paemeleire K, Goadsby PJ, MaassenVanDenBrink A, et al
   What's a migraine day? Analysis of the variety in the definition of a migraine day across phase III trials with drugs targeting the CGRP pathway.
   Cephalalgia. 2025;45:3331024251393986.
   PubMed     Abstract available
   
   
   
7. ZORRILLA E, Duong TL, Pina CL, Russo AF, et al
   Cannabinoids rescue migraine symptoms caused by central CGRP administration in mice.
   Cephalalgia. 2025;45:3331024251392103.
   PubMed     Abstract available
   
   
   
8. DUMKRIEGER G
   The promise of machine learning in predicting migraine attacks.
   Cephalalgia. 2025;45:3331024251391207.
   PubMed     Abstract available
   
   
   
9. LIN C, Li Y, Wang Z, Duan C, et al
   Abnormal neurovascular coupling in the precuneus associated with migraine chronification: A multimodal magnetic resonance imaging study.
   Cephalalgia. 2025;45:3331024251396031.
   PubMed     Abstract available
   
   
   
10. PARDO K, Schwedt TJ, Cutrer FM, Chiang CC, et al
    The promise of artificial intelligence and machine learning for migraine treatment outcome prediction: A narrative review.
    Cephalalgia. 2025;45:3331024251395541.
    PubMed     Abstract available
    
    
    
11. ORNELLO R, Maassen van den Brink A, Puledda F, Sandoe CH, et al
    Migraine management during pregnancy, breastfeeding and in women planning pregnancy.
    Cephalalgia. 2025;45:3331024251393945.
    PubMed     Abstract available
    
    
    
12. POZO-ROSICH P, Lopez JAG, Lisewski P, Aslan AN, et al
    A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications.
    Cephalalgia. 2025;45:3331024251391378.
    PubMed     Abstract available
    
    
    
13. ASHINA M, McAllister P, Gaul C, Leyva-Rendon A, et al
    Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.
    Cephalalgia. 2025;45:3331024251395298.
    PubMed     Abstract available
    
    
    
14. TANG Y, Li H, Dong B, Sha L, et al
    Divergent functional connectivity patterns in menstrually-related and non-menstrual migraine: A large-scale resting-state fMRI study.
    Cephalalgia. 2025;45:3331024251396102.
    PubMed     Abstract available
    
    
    
15. PISTOLESI A, De Cesaris F, Buonvicino D, Chiarugi A, et al
    Biodistribution of atogepant and rimegepant in mouse peripheral and central structures of relevance to migraine pathogenesis.
    Cephalalgia. 2025;45:3331024251378713.
    PubMed     Abstract available
    
    
    October 2025
16. PERES MFP, Yuan H, Tassorelli C
    Complementary, but not equivalent: Clarifying the role of RWE and RCT in migraine research.
    Cephalalgia. 2025;45:3331024251381333.
    PubMed    
    
    
    
17. PERES MFP, Yuan H, Tassorelli C
    The importance of treating migraine attacks early - even in youth: A real-world argument for neuromodulation.
    Cephalalgia. 2025;45:3331024251370675.
    PubMed    
    
    
    
18. LAX DN, Stark-Inbar A, Ironi A, Tomaschek I, et al
    It's not either-or: Why migraine care needs both real-world evidence studies and randomized controlled trials.
    Cephalalgia. 2025;45:3331024251381337.
    PubMed    
    
    
    
19. ZHANG M, Guo A, Wu J, Wang H, et al
    Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.
    Cephalalgia. 2025;45:3331024251371686.
    PubMed     Abstract available
    
    
    
20. TAMAYO DE LEON CD, Gama-Reyes EG, Paredes Moreno FA, Galnares-Olalde JA, et al
    Adjunctive occipital nerve block for emergency treatment of acute migraine: A randomized, controlled trial.
    Cephalalgia. 2025;45:3331024251381764.
    PubMed     Abstract available
    
    
    
21. YU S, Matsumori Y, Kim BK, Gryglas-Dworak A, et al
    Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.
    Cephalalgia. 2025;45:3331024251386095.
    PubMed     Abstract available
    
    
    
22. POZO-ROSICH P, Blumenfeld AM, Lipton RB, DeGryse RE, et al
    OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial.
    Cephalalgia. 2025;45:3331024251370769.
    PubMed     Abstract available
    
    
    
23. DA LUZ FMR, Kaup AO, Baggio DF, Costa FHR, et al
    Efficacy of different cannabinoid compounds on migraine-like responses in female rats.
    Cephalalgia. 2025;45:3331024251386794.
    PubMed     Abstract available
    
    
    
24. MCCAIN CR, Parrish MH, Melikov P, Rosamond WD, et al
    Introducing a risk score for predicting ischemic stroke in migraine with or without visual aura.
    Cephalalgia. 2025;45:3331024251388094.
    PubMed     Abstract available
    
    
    
25. YUAN H, Orr SL, Al-Karagholi MAM, Ashina M, et al
    International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.
    Cephalalgia. 2025;45:3331024251388377.
    PubMed     Abstract available
    
    
    
26. GARCIA LB, Ferreira AJ, Hussein MA, Kowacs PA, et al
    What does ChatGPT know about Migraine? A comparative-descriptive analysis.
    Cephalalgia. 2025;45:3331024251387684.
    PubMed     Abstract available
    
    
    
27. SILVA NVD, Bevilaqua-Grossi D, Pradela J, Dach F, et al
    Cervical musculoskeletal dysfunctions in pediatric migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251387033.
    PubMed     Abstract available
    
    
    
28. FOFI L, Altamura C, Marcosano M, Brunelli N, et al
    The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments.
    Cephalalgia. 2025;45:3331024251378776.
    PubMed     Abstract available
    
    
    
29. MATHARU MS, Silberstein S, Yuan H, Edgar D, et al
    Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis.
    Cephalalgia. 2025;45:3331024251385965.
    PubMed     Abstract available
    
    
    
30. MASCARELLA D, Zhuang ZA, Gliga O, Santis F, et al
    Migraine in monogenic disorders: Shedding light on new therapeutic targets.
    Cephalalgia. 2025;45:3331024251389241.
    PubMed     Abstract available
    
    
    
31. OLIVEIRA AB, Barbosa F Jr, Santos IS, Peres MFP, et al
    Selenium levels as a sex-specific predictor of migraine in the ELSA-Brasil study.
    Cephalalgia. 2025;45:3331024251386768.
    PubMed     Abstract available
    
    
    
32. BOTROS J, Metzler AI, Darrow DP, Peterson CM, et al
    Toward ICHD-4: Aligning ICHD and ICOP criteria for trigeminal autonomic cephalalgias and migraine.
    Cephalalgia. 2025;45:3331024251391751.
    PubMed    
    
    
    
33. POZO-ROSICH P, Caronna E, Sacco S, Peres MFP, et al
    Early treatment in migraine - A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society.
    Cephalalgia. 2025;45:3331024251387721.
    PubMed     Abstract available
    
    
    
34. REES TA, Doukhi D, Wang VS, Balcerbula A, et al
    Neck pain in migraine: A narrative review and steps to correct evaluation and treatment.
    Cephalalgia. 2025;45:3331024251387449.
    PubMed     Abstract available
    
    
    
35. AILANI J, Tomaschek I, Stark-Inbar A, Shmuely S, et al
    The effect of treatment onset time on acute efficacy in migraine patients treating with remote electrical neuromodulation (REN).
    Cephalalgia. 2025;45:3331024251370696.
    PubMed     Abstract available
    
    
    September 2025
36. GOADSBY PJ, Ruiz de la Torre E, Maassen van den Brink A, Irimia P, et al
    Migraine stigma and general knowledge of migraine: A cross-sectional European survey.
    Cephalalgia. 2025;45:3331024251368251.
    PubMed     Abstract available
    
    
    
37. IFERGANE G
    Reinterpreting migraine in a societal evolutionary context.
    Cephalalgia. 2025;45:3331024251374315.
    PubMed    
    
    
    
38. MOSKOWITZ MA
    Rethinking migraine with aura: Why cortical spreading depolarization (depression), not aura, causes headaches.
    Cephalalgia. 2025;45:3331024251370629.
    PubMed     Abstract available
    
    
    
39. VIANA M, Peres MFP
    The spectrum of migraine aura: Towards a precise phenotypic classification.
    Cephalalgia. 2025;45:3331024251372621.
    PubMed     Abstract available
    
    
    
40. CASILLO F, Sebastianelli G, Abagnale C, Di Renzo A, et al
    Brain imaging in migraine with and without aura: Similarities and differences.
    Cephalalgia. 2025;45:3331024251365807.
    PubMed     Abstract available
    
    
    
41. ROMERO-REYES M, Akerman S, Rapoport AM
    Optimising combined treatment for migraine and temporomandibular disorders (TMDs).
    Cephalalgia. 2025;45:3331024251368882.
    PubMed     Abstract available
    
    
    
42. FERNANDES C, Gil-Gouveia R
    Deciphering the mechanisms: Pathophysiology of migraine-related cognitive dysfunction.
    Cephalalgia. 2025;45:3331024251368328.
    PubMed     Abstract available
    
    
    
43. PIETRA AD, Kuburas A, Russo AF
    PACAP versus CGRP in migraine: From mouse models to clinical translation.
    Cephalalgia. 2025;45:3331024251364242.
    PubMed     Abstract available
    
    
    
44. CLEMENTE L, Paparella G, Scannicchio S, Abbatantuono C, et al
    Dorso lateral prefrontal cortex stimulation with TMS in chronic migraine individuals refractory to anti-CGRP monoclonal antibodies: Clinical, neuropsychological and neurophysiological effects.
    Cephalalgia. 2025;45:3331024251364843.
    PubMed     Abstract available
    
    
    
45. ROBBLEE J, Khan FA, Marmura MJ, O'Brien HL, et al
    Reaching international consensus on the definition of refractory migraine using the Delphi method.
    Cephalalgia. 2025;45:3331024251367767.
    PubMed     Abstract available
    
    
    
46. BRACA S, Santoro V, Sebastianelli G, Schankin CJ, et al
    Visual snow vs. migraine aura: Debate summary and novel insights into the syndrome.
    Cephalalgia. 2025;45:3331024251365908.
    PubMed     Abstract available
    
    
    
47. SCHAIN AJ, Delgado Fajardo D, Strassman AM, Kulkarni S, et al
    OnabotulinumtoxinA alters pro- and anti-inflammatory dural macrophage response to CSD in female mice.
    Cephalalgia. 2025;45:3331024251378730.
    PubMed     Abstract available
    
    
    
48. MATSUMORI Y, Yamada H, Nagaseki Y, Shimizu K, et al
    Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE).
    Cephalalgia. 2025;45:3331024251374569.
    PubMed     Abstract available
    
    
    August 2025
49. ALPAY B, Christensen RH, Al-Khazali HM, Ashina M, et al
    Substance P and the trigeminovascular system: From preclinical mechanisms to human headache induction.
    Cephalalgia. 2025;45:3331024251355944.
    PubMed     Abstract available
    
    
    
50. VAGHI G, Corrado M, Pocora MM, Bighiani F, et al
    Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis.
    Cephalalgia. 2025;45:3331024251353421.
    PubMed     Abstract available
    
    
    
51. TASMA Z, Hay DL
    Decoding PACAP signaling: Splice variants, pathways and designer drugs.
    Cephalalgia. 2025;45:3331024251363560.
    PubMed     Abstract available
    
    
    
52. SACCO S
    The "Migraines" epidemic: Exposing the challenges of artificial intelligence in scientific writing.
    Cephalalgia. 2025;45:3331024251365833.
    PubMed    
    
    
    
53. VALENCA MM
    Proposal of a migraine with associated myofascial pain phenotype: Bridging corpalgia, fibromyalgia and chronic migraine.
    Cephalalgia. 2025;45:3331024251360223.
    PubMed    
    
    
    
54. VAN VEELEN N, Pelzer N, van der Arend BWH, Waslam N, et al
    The psychometric properties of an e-headache diary in migraine.
    Cephalalgia. 2025;45:3331024251359222.
    PubMed     Abstract available
    
    
    
55. CHRISTENSEN RH, Strassman AM, Ashina M, Ashina H, et al
    Opening of ATP-sensitive potassium channels activates meningeal nociceptors: Implications for the origin of migraine headache.
    Cephalalgia. 2025;45:3331024251359237.
    PubMed     Abstract available
    
    
    
56. DOMINGUEZ-MORENO R, Karlsson WK, Al-Khazali HM, Christensen RH, et al
    Plasma adrenomedullin levels in migraine: A registry for migraine (REFORM) study.
    Cephalalgia. 2025;45:3331024251360234.
    PubMed     Abstract available
    
    
    
57. CHRISTENSEN RH, Al-Khazali HM, Ashina M, Vashchenko N, et al
    Differences in cortical morphometry between persistent post-traumatic headache, migraine and healthy controls.
    Cephalalgia. 2025;45:3331024251362830.
    PubMed     Abstract available
    
    
    
58. JOHNSON MP, Krikke-Workel J, Patel CN, Morin SM, et al
    Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine.
    Cephalalgia. 2025;45:3331024251368757.
    PubMed     Abstract available
    
    
    
59. FERREIRA KDS, Velly AM
    Acute confusional migraine: Proposal for inclusion in the International Classification of Headache Disorders - 4th edition (ICHD-4).
    Cephalalgia. 2025;45:3331024251370305.
    PubMed    
    
    
    
60. ASHINA S, Ashina M, Holle-Lee D, Tassorelli C, et al
    Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.
    Cephalalgia. 2025;45:3331024251365206.
    PubMed     Abstract available
    
    
    
61. EDVINSSON L
    Is PACAP the next big thing in migraine therapy?
    Cephalalgia. 2025;45:3331024251368748.
    PubMed    
    
    
    
62. PELES I, Sharvit S, Steen YM, Gordon M, et al
    Invisible burdens: Gender-specific associations between migraine and work-family conflict: Insights from the SMILE project - a cohort study.
    Cephalalgia. 2025;45:3331024251352533.
    PubMed     Abstract available
    
    
    
63. RUSSO A, Silvestro M, Finkelstein I, Seabi D, et al
    Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence.
    Cephalalgia. 2025;45:3331024251370608.
    PubMed     Abstract available
    
    
    
64. THURAIAIYAH J, Christensen RH, Al-Khazali HM, Wiggers A, et al
    Overlap between perceived triggers, premonitory symptoms and symptom persistence across migraine phases: A REFORM study.
    Cephalalgia. 2025;45:3331024251364234.
    PubMed     Abstract available
    
    
    
65. ZHAI Q, Li H, Chen Q, Zhang N, et al
    Microglial TRPV2-mediated neuroinflammation promotes central sensitization through microglial polarization in a vestibular migraine mouse model.
    Cephalalgia. 2025;45:3331024251364753.
    PubMed     Abstract available
    
    
    July 2025
66. CHAN NJ, Chen YY, Hsu CC, Lin YS, et al
    Sensitizing effect of antimigraine drug sumatriptan on capsaicin-sensitive lung vagal neurons via 5-HT(1B/1D) receptors and PKA: Relevance to adverse chest effects.
    Cephalalgia. 2025;45:3331024251355949.
    PubMed     Abstract available
    
    
    
67. ROMOZZI M, Scipioni L, Di Tella S, Silveri MC, et al
    Genetic characterization of the endocannabinoid system and psychiatric features in patients with migraine and medication overuse headache.
    Cephalalgia. 2025;45:3331024251314460.
    PubMed     Abstract available
    
    
    
68. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
    Grey-matter network topology in migraine with aura.
    Cephalalgia. 2025;45:3331024251353146.
    PubMed     Abstract available
    
    
    
69. NIELSEN BS, Wang H, Ramdal Techlo T, Kogelman L, et al
    Genome sequencing reveals the Adgrl3 (ADGRL3) gene as a possible cause of cephalic hypersensitivity in the STA rat and migraine in humans.
    Cephalalgia. 2025;45:3331024251352844.
    PubMed     Abstract available
    
    
    
70. HU YY, Mei HR, Sankar S, Pirwani A, et al
    Post-stress modulation of the HPA and melanocortin systems alleviates migraine-like behaviors in mice.
    Cephalalgia. 2025;45:3331024251352856.
    PubMed     Abstract available
    
    
    
71. AILANI J, Pavlovic J, Pixton GC, Fullerton T, et al
    Rimegepant safety and patient-reported outcomes among triptan-naive, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study.
    Cephalalgia. 2025;45:3331024251343309.
    PubMed     Abstract available
    
    
    
72. ZHUANG ZA, Al-Karagholi MA, Ashina H, Do TP, et al
    Effect of sumatriptan on ATP-sensitive potassium channel opening in migraine: A randomised controlled trial.
    Cephalalgia. 2025;45:3331024251341464.
    PubMed     Abstract available
    
    
    
73. ANDREOU AP, Iannone LF
    The ongoing pursuit of migraine triggering mechanisms.
    Cephalalgia. 2025;45:3331024251342583.
    PubMed    
    
    
    
74. VILLAR-MARTINEZ MD, Goadsby PJ
    Cranial autonomic symptoms as a protective mechanism in patients with chronic migraine: A cross-sectional study.
    Cephalalgia. 2025;45:3331024251359564.
    PubMed     Abstract available
    
    
    
75. BOTTIROLI S, Cangelosi M, Allena M, Icco R, et al
    Childhood traumas delineate a distinct psychological and clinical profile in adults with migraine: The hidden burden.
    Cephalalgia. 2025;45:3331024251358503.
    PubMed     Abstract available
    
    
    
76. BOCZARSKA-JEDYNAK M, Blumenfeld AM
    When should the effectiveness of a botulinum toxin A for chronic migraine be assessed in the face of newest International Headache Society recommendations?
    Cephalalgia. 2025;45:3331024251363268.
    PubMed    
    
    
    
77. ALSAADI T, Suliman R, Yang J, Agarwal E, et al
    A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.
    Cephalalgia. 2025;45:3331024251355947.
    PubMed     Abstract available
    
    
    
78. PETRUSIC I
    Digital phenotyping for migraine: A game-changer for research and management.
    Cephalalgia. 2025;45:3331024251363568.
    PubMed     Abstract available
    
    
    
79. SUZUKI Y, Kiyosawa M
    Characteristics of visual snow syndrome in Japan and its association with migraine.
    Cephalalgia. 2025;45:3331024251360337.
    PubMed     Abstract available
    
    
    
80. TEPPER SJ, Jenkins A, Henriksen C, Dai F, et al
    A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: A retrospective analysis of US claims data.
    Cephalalgia. 2025;45:3331024251352849.
    PubMed     Abstract available
    
    
    June 2025
81. CHAUDHRY BA, Younis S, Messina R, Garcia-Azorin D, et al
    Cortical thickness studies in migraine: Current evidence and future directions.
    Cephalalgia. 2025;45:3331024251341204.
    PubMed     Abstract available
    
    
    
82. SILVESTRO M, Orologio I, Sozio P, Dortucci V, et al
    No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies.
    Cephalalgia. 2025;45:3331024251329808.
    PubMed     Abstract available
    
    
    
83. JAIMES A, Rodriguez-Vico J, Pajares O, Eguilior Caffarena I, et al
    Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study.
    Cephalalgia. 2025;45:3331024251346925.
    PubMed     Abstract available
    
    
    
84. ASHINA S, Kim G, Muenzel EJ, Buse DC, et al
    Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study.
    Cephalalgia. 2025;45:3331024251341243.
    PubMed     Abstract available
    
    
    
85. WENNERSTEN T, Lindh JD, Nilsson Remahl AIM, Andersson ML, et al
    Higher socioeconomic status is associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide in migraine: A nested case-control study.
    Cephalalgia. 2025;45:3331024251348648.
    PubMed     Abstract available
    
    
    
86. LING YH, Pan LH, Chen SP, Chen WT, et al
    Comorbidity with fibromyalgia predicted poorer outcomes in patients with chronic migraine on flunarizine: Prospective proof-of-concept study.
    Cephalalgia. 2025;45:3331024251353412.
    PubMed     Abstract available
    
    
    May 2025
87. WONG HT, Khan R, Buture A, Khalil M, et al
    OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull.
    Cephalalgia. 2025;45:3331024251327387.
    PubMed     Abstract available
    
    
    
88. EMMENEGGER MJ, Gantenbein AR
    Philosophical aspects of migraine: Headache treatment is a human-to-human service.
    Cephalalgia. 2025;45:3331024251343225.
    PubMed     Abstract available
    
    
    
89. SORRENTINO A, Di Lorenzo C
    Comment on: Setting higher standards for migraine prevention: A position statement of the International Headache Society.
    Cephalalgia. 2025;45:3331024251343217.
    PubMed    
    
    
    
90. GOZALOV E, Karlsson WK, Christensen RH, Al-Khazali HM, et al
    Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study.
    Cephalalgia. 2025;45:3331024251338178.
    PubMed     Abstract available
    
    
    
91. PORRECA F, Navratilova E, Dodick DW
    Advancing understanding of migraine pathophysiology and therapy by consideration of patient sex.
    Cephalalgia. 2025;45:3331024251339466.
    PubMed     Abstract available
    
    
    
92. MORENO-AJONA D, Gosalia H, Hoffmann J, Goadsby PJ, et al
    Amylin and the amylin receptors in migraine: Is there another pathway to target?
    Cephalalgia. 2025;45:3331024251340066.
    PubMed     Abstract available
    
    
    
93. RUSSO A, Reuter U
    Raising the bar in migraine prevention: Toward freedom and optimal control.
    Cephalalgia. 2025;45:3331024251331198.
    PubMed    
    
    
    
94. ORNELLO R, D'Atri A, De Icco R, De Santis F, et al
    Effectiveness of transcranial direct current stimulation and monoclonal antibodies acting on the CGRP as a combined treatment for migraine (TACTIC): Results of a randomized controlled trial.
    Cephalalgia. 2025;45:3331024251325567.
    PubMed     Abstract available
    
    
    
95. GOLLION C, Ashina H, Hackert Christensen R, Al-Khazali HM, et al
    Intact white matter in adults with migraine: A REFORM MRI study.
    Cephalalgia. 2025;45:3331024251339423.
    PubMed     Abstract available
    
    
    April 2025
96. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
    Reply to "What is the evolutionary disadvantage of migraine?".
    Cephalalgia. 2025;45:3331024251327377.
    PubMed    
    
    
    
97. LISICKI M, Schoenen J
    What is the evolutionary disadvantage of migraine?
    Cephalalgia. 2025;45:3331024251327361.
    PubMed    
    
    
    
98. MAS-DE-LES-VALLS R, Gomez-Dabo L, Caronna E, Gallardo VJ, et al
    Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days.
    Cephalalgia. 2025;45:3331024251332519.
    PubMed     Abstract available
    
    
    
99. VALENCA MM, Szewczyk AK
    Stroke-like migraine attacks after radiation therapy (SMART) syndrome: A call for standardized diagnostic criteria.
    Cephalalgia. 2025;45:3331024251334355.
    PubMed    
    
    
    
100. ROBBLEE J
     Rethinking status migrainosus: Escalation shouldn't wait for 72 hours.
     Cephalalgia. 2025;45:3331024251334137.
     PubMed    
     
     
     
101. VERNIERI F, Iannone LF, Lo Castro F, Sebastianelli G, et al
     Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).
     Cephalalgia. 2025;45:3331024251335927.
     PubMed     Abstract available
     
     
     
102. HAGHDOOST F
     Internet and social media's role in migraine education: Headache or not headache?
     Cephalalgia. 2025;45:3331024251336152.
     PubMed    
     
     
     
103. AL-KHAZALI HM, Christensen RH, Ashina H
     Clinical comparisons between post-traumatic headache and migraine: A cross-sectional study.
     Cephalalgia. 2025;45:3331024251331605.
     PubMed     Abstract available
     
     
     
104. GONZALEZ-MARTINEZ A, Wei DY, Karsan N, Nagaraj K, et al
     Evaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine.
     Cephalalgia. 2025;45:3331024251331554.
     PubMed     Abstract available
     
     
     
105. MESSINA R, Chong CD
     Migraine and the white matter microstructure controversy: Time for a methodological reset?
     Cephalalgia. 2025;45:3331024251339431.
     PubMed    
     
     
     
106. SEBASTIANELLI G
     The 'theory of everything' for migraine pathophysiology will never exist: Insights from glial cells.
     Cephalalgia. 2025;45:3331024251338171.
     PubMed    
     
     
     
107. ORNELLO R, Caponnetto V, Ahmed F, Al-Khazali HM, et al
     Evidence-based guidelines for the pharmacological treatment of migraine, summary version.
     Cephalalgia. 2025;45:3331024251321500.
     PubMed     Abstract available
     
     
     
108. ORNELLO R, Caponnetto V, Ahmed F, Al-Khazali HM, et al
     Evidence-based guidelines for the pharmacological treatment of migraine.
     Cephalalgia. 2025;45:3331024241305381.
     PubMed     Abstract available
     
     
     March 2025
109. OMLAND PM, Hansen JO, Neverdahl JP, Mykland MS, et al
     Migraine and insufficient sleep: The effect of sleep restriction on nociceptive evoked potentials in migraine.
     Cephalalgia. 2025;45:3331024251329400.
     PubMed     Abstract available
     
     
     
110. PULEDDA F, Tassorelli C
     Reply to "Reassessing partial efficacy or not responding to acute migraine treatment".
     Cephalalgia. 2025;45:3331024251325543.
     PubMed    
     
     
     
111. POZO-ROSICH P, van Veelen N, Caronna E, Vaghi G, et al
     Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache.
     Cephalalgia. 2025;45:3331024251318016.
     PubMed     Abstract available
     
     
     
112. YANG L, Jin T, Wang H
     Reassessing partial efficacy or not responding to acute migraine treatment.
     Cephalalgia. 2025;45:3331024251325526.
     PubMed    
     
     
     
113. BAI Y, Chu MK, Kang JJ, Chae J, et al
     No change in interictal plasma and salivary CGRP levels in individuals with vestibular migraine corresponding to episodic migraine.
     Cephalalgia. 2025;45:3331024251322418.
     PubMed     Abstract available
     
     
     February 2025
114. GUZMAN G, Kopruszinski CM, Barber KR, Lillo Vizin RC, et al
     Chronification of migraine sensitizes to CGRP in male and female mice.
     Cephalalgia. 2025;45:3331024251317446.
     PubMed     Abstract available
     
     
     
115. CHEEMA S, Lagrata S, Rantell KR, Ahmed M, et al
     OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine.
     Cephalalgia. 2025;45:3331024251317448.
     PubMed     Abstract available
     
     
     
116. GANTENBEIN AR
     Depression screening in migraine - A double-edged sword.
     Cephalalgia. 2025;45:3331024251317606.
     PubMed    
     
     
     
117. GOADSBY PJ, Jurgens TP, Brand-Schieber E, Nagy K, et al
     Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.
     Cephalalgia. 2025;45:3331024251320610.
     PubMed     Abstract available
     
     
     
118. SACCO S, Ashina M, Diener HC, Haghdoost F, et al
     Setting higher standards for migraine prevention: A position statement of the International Headache Society.
     Cephalalgia. 2025;45:3331024251320608.
     PubMed     Abstract available
     
     
     
119. ASHEER J, Ali F, Hilker R, Videbech P, et al
     Methodological challenges in using screening tools for depression in migraine: A systematic review.
     Cephalalgia. 2025;45:3331024251317635.
     PubMed     Abstract available
     
     
     
120. SZABO E, Bolo NR, Borsook D, Burstein R, et al
     Peripherally acting anti-CGRP monoclonal antibodies attenuate cortical resting-state connectivity in migraine patients.
     Cephalalgia. 2025;45:3331024241313377.
     PubMed     Abstract available
     
     
     
121. LIAO YH, Tzeng YS, Chen SP, Ling YH, et al
     Association between headache frequency and risk for fibromyalgia in patients with migraine.
     Cephalalgia. 2025;45:3331024251317486.
     PubMed     Abstract available
     
     
     
122. ZORRILLA E, Krivoshein G, Kuburas A, Schenke M, et al
     Combined effects of cannabidiol and Delta9-tetrahydrocannabinol alleviate migraine-like symptoms in mice.
     Cephalalgia. 2025;45:3331024251314487.
     PubMed     Abstract available
     
     
     January 2025
123. STAEHR C, Nyegaard M, Bach FW, Rohde PD, et al
     Exploring the association between familial hemiplegic migraine genes (CACNA1A, ATP1A2 and SCN1A) with migraine and epilepsy: A UK Biobank exome-wide association study.
     Cephalalgia. 2025;45:3331024241306103.
     PubMed     Abstract available
     
     
     
124. MOHAMMAD S, Bussu G, Rukh G, Schioth HB, et al
     Migraine and its major subtypes - with and without aura are associated with polygenic scores for autism.
     Cephalalgia. 2025;45:3331024241312666.
     PubMed     Abstract available
     
     
     
125. LEE GJ, Hode V, Georgieva T, Rau J, et al
     Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis.
     Cephalalgia. 2025;45:3331024241313378.
     PubMed     Abstract available
     
     
     
126. VAN DER AREND BWH, van Welie FC, Olsen MH, Versijpt J, et al
     Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine: A systematic review and potential clinical implications.
     Cephalalgia. 2025;45:3331024241297673.
     PubMed     Abstract available
     
     
     December 2024
127. GENDOLLA A, Brown JD, Mercadante AR, Drakeley S, et al
     The incremental burden and healthcare resource utilization among people with migraine in Europe: Insights from the 2020 European National Health and Wellness Survey.
     Cephalalgia. 2024;44:3331024241276415.
     PubMed     Abstract available
     
     
     
128. 
     Abstracts of the 20(th) Biennial Migraine Trust International Symposium, London UK, 5th to 8th September 2024.
     Cephalalgia. 2024;44:3331024241280496.
     PubMed    
     
     
     
129. OLESEN J, Tfelt-Hansen P
     Methodology of drug trials in migraine: History and suggestions for the future.
     Cephalalgia. 2024;44:3331024241298642.
     PubMed     Abstract available
     
     
     
130. ROMOZZI M, Lokhandwala A, Vollono C, Vigani G, et al
     An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine.
     Cephalalgia. 2024;44:3331024241262751.
     PubMed     Abstract available
     
     
     
131. PETERLIN BL, Bond DS, Ailani J, Dodick DW, et al
     Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis.
     Cephalalgia. 2024;44:3331024241299753.
     PubMed     Abstract available
     
     
     
132. GOTTSCHALK C, Gandhi P, Pozo-Rosich P, Christie S, et al
     Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.
     Cephalalgia. 2024;44:3331024241300305.
     PubMed     Abstract available
     
     
     November 2024
133. BURGALASSI A, Romozzi M, Vigani G, De Icco R, et al
     Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.
     Cephalalgia. 2024;44:3331024241273968.
     PubMed     Abstract available
     
     
     
134. SACCO S, De Santis F, Onofri A, Rosignoli C, et al
     A call for academic pragmatic clinical trials to address open questions in migraine prevention.
     Cephalalgia. 2024;44:3331024241291574.
     PubMed     Abstract available
     
     
     
135. CLOET F, Gueyraud G, Lerebours F, Munio M, et al
     Stroke due to small-vessel disease and migraine: A case-control study of a young adult with ischemic stroke population.
     Cephalalgia. 2024;44:3331024241282015.
     PubMed     Abstract available
     
     
     
136. AILANI J, Lalla A, Halker Singh RB, Holle-Lee D, et al
     Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.
     Cephalalgia. 2024;44:3331024241299377.
     PubMed     Abstract available
     
     
     
137. PULEDDA F, de Boer I, Messina R, Garcia-Azorin D, et al
     Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society.
     Cephalalgia. 2024;44:3331024241297688.
     PubMed     Abstract available
     
     
     
138. YANG C, Wei C, Alam S, Chen X, et al
     The neurotrophic factor artemin and its receptor GFRalpha3 mediate migraine-like pain via the ion channel TRPM8.
     Cephalalgia. 2024;44:3331024241297679.
     PubMed     Abstract available
     
     
     
139. DALLA VOLTA G, Russo A, Silvestro M, Ornello R, et al
     Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.
     Cephalalgia. 2024;44:3331024241299453.
     PubMed     Abstract available
     
     
     October 2024
140. SEBASTIANELLI G, Atalar AC, Cetta I, Farham F, et al
     Insights from triggers and prodromal symptoms on how migraine attacks start: The threshold hypothesis.
     Cephalalgia. 2024;44:3331024241287224.
     PubMed     Abstract available
     
     
     
141. PELES I, Sharvit S, Zlotnik Y, Gordon M, et al
     Migraine and work - beyond absenteeism: Migraine severity and occupational burnout - A cohort study.
     Cephalalgia. 2024;44:3331024241289930.
     PubMed     Abstract available
     
     
     
142. CAMMAROTA F, De Icco R, Vaghi G, Corrado M, et al
     High-frequency episodic migraine: Time for its recognition as a migraine subtype?
     Cephalalgia. 2024;44:3331024241291578.
     PubMed     Abstract available
     
     
     
143. TRILLER P, Blessing VN, Overeem LH, Fitzek MP, et al
     Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study.
     Cephalalgia. 2024;44:3331024241288875.
     PubMed     Abstract available
     
     
     September 2024
144. ACARSOY C, Ikram MK, Ikram MA, Vernooij MW, et al
     Migraine and brain structure in the elderly: The Rotterdam Study.
     Cephalalgia. 2024;44:3331024241266951.
     PubMed     Abstract available
     
     
     
145. KOPRUSZINSKI CM, Lee G, Martin LK, Barber KR, et al
     A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache.
     Cephalalgia. 2024;44:3331024241281493.
     PubMed     Abstract available
     
     
     
146. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
     International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine.
     Cephalalgia. 2024;44:3331024241269735.
     PubMed    
     
     
     
147. IHARA K, Casillo F, Dahshan A, Genc H, et al
     Are we closer to achieving precision medicine for migraine treatment? A narrative review.
     Cephalalgia. 2024;44:3331024241281518.
     PubMed     Abstract available
     
     
     
148. MELO-CARRILLO A, Strassman AM, Malcolm KJ, Adams AM, et al
     Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats.
     Cephalalgia. 2024;44:3331024241278919.
     PubMed     Abstract available
     
     
     
149. WILCHA RJ, Goadsby PJ
     Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study.
     Cephalalgia. 2024;44:3331024241278911.
     PubMed     Abstract available
     
     
     
150. CASILLO F, Di Renzo A, Sebastianelli G, Abagnale C, et al
     Lack of a direct link between macular cones function and photophobia in interictal migraine.
     Cephalalgia. 2024;44:3331024241276501.
     PubMed     Abstract available
     
     
     
151. ASHINA M, Steiner TJ, Hansen JM, Hauberg DS, et al
     Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021.
     Cephalalgia. 2024;44:3331024241269758.
     PubMed     Abstract available
     
     
     
152. ERNSTSEN C, Obelitz-Ryom K, Kristensen DMB, Olesen J, et al
     Mechanisms of GTN-induced migraine: Role of NOS isoforms, sGC and peroxynitrite in a migraine relevant mouse model.
     Cephalalgia. 2024;44:3331024241277542.
     PubMed     Abstract available
     
     
     
153. ELOSUA-BAYES I, Alpuente A, Melgarejo L, Caronna E, et al
     Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data.
     Cephalalgia. 2024;44:3331024241273966.
     PubMed     Abstract available
     
     
     August 2024
154. DO TP
     Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications.
     Cephalalgia. 2024;44:3331024241268058.
     PubMed    
     
     
     
155. OMLAND PM
     Enhanced learning in migraine: False positive finding or discovery of a new migraine trait?
     Cephalalgia. 2024;44:3331024241268297.
     PubMed    
     
     
     
156. STUBBERUD A, Borkenhagen S, Oteiza F, Dueland AN, et al
     Patterns of migraine medication use in Norway: A nationwide registry-based observational study.
     Cephalalgia. 2024;44:3331024241268212.
     PubMed     Abstract available
     
     
     
157. PULEDDA F, Sacco S, Diener HC, Ashina M, et al
     International Headache Society global practice recommendations for the acute pharmacological treatment of migraine.
     Cephalalgia. 2024;44:3331024241252666.
     PubMed     Abstract available
     
     
     
158. KATSARAVA Z, Buse DC, Leroux E, Lanteri-Minet M, et al
     Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study.
     Cephalalgia. 2024;44:3331024241274343.
     PubMed     Abstract available
     
     
     
159. SIMMONDS L, Jamtoy KA, Aschehoug I, Hara S, et al
     Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine.
     Cephalalgia. 2024;44:3331024241273967.
     PubMed     Abstract available
     
     
     
160. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
     Effects of levcromakalim in patients with migraine aura without headache: An experimental study.
     Cephalalgia. 2024;44:3331024241274366.
     PubMed     Abstract available
     
     
     
161. HU YY, Souza R, Muthuraman A, Knapp L, et al
     Glucocorticoid signaling mediates stress-induced migraine-like behaviors in a preclinical mouse model.
     Cephalalgia. 2024;44:3331024241277941.
     PubMed     Abstract available
     
     
     
162. MULLIN K, Croop R, Mosher L, Fullerton T, et al
     Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
     Cephalalgia. 2024;44:3331024241259456.
     PubMed     Abstract available
     
     
     
163. AL-KHAZALI HM, Al-Sayegh Z, Younis S, Christensen RH, et al
     Systematic review and meta-analysis of Neck Disability Index and Numeric Pain Rating Scale in patients with migraine and tension-type headache.
     Cephalalgia. 2024;44:3331024241274266.
     PubMed     Abstract available
     
     
     
164. PERES MFP, Sacco S, Pozo-Rosich P, Tassorelli C, et al
     Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action.
     Cephalalgia. 2024;44:3331024241267309.
     PubMed     Abstract available
     
     
     July 2024
165. RUSCHEWEYH R, Forderreuther S, Freilinger T, Gaul C, et al
     Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry.
     Cephalalgia. 2024 Jul 21:3331024241261077. doi: 10.1177/03331024241261077.
     PubMed     Abstract available
     
     
     
166. DE VRIES T, Boucherie DM, Chan KY, Rubio-Beltran E, et al
     Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine.
     Cephalalgia. 2024;44:3331024241254088.
     PubMed     Abstract available
     
     
     
167. TOT K, Braunitzer G, Harcsa-Pinter N, Kiss A, et al
     Enhanced audiovisual associative pair learning in migraine without aura in adult patients: An unexpected finding.
     Cephalalgia. 2024;44:3331024241258722.
     PubMed     Abstract available
     
     
     June 2024
168. EXACOUSTOS C, Martire FG, Albanese M, Selntigia A, et al
     REPLY to Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': Correlation between endometriosis and migraine features is not based on a broad strokes results.
     Cephalalgia. 2024;44:3331024241254821.
     PubMed    
     
     
     
169. LIU L, Chen Q, Zhao L, Lyu T, et al
     Acupuncture plus topiramate placebo versus topiramate plus sham acupuncture for the preventive treatment of chronic migraine: A single-blind, double-dummy, randomized controlled trial.
     Cephalalgia. 2024;44:3331024241261080.
     PubMed     Abstract available
     
     
     
170. ISHII R, Ishizuchi K, Watanabe N, Fukazawa R, et al
     Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
     Cephalalgia. 2024;44:3331024241258695.
     PubMed     Abstract available
     
     
     
171. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
     Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.
     Cephalalgia. 2024;44:3331024241258734.
     PubMed     Abstract available
     
     
     
172. RAFFAELLI B, Do TP, Ashina H, Snellman J, et al
     Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation.
     Cephalalgia. 2024;44:3331024241259489.
     PubMed     Abstract available
     
     
     
173. LI H, Xu X, Xu R, Fan PX, et al
     Latent class analysis of migraine associated vestibular-auditory symptoms.
     Cephalalgia. 2024;44:3331024241262488.
     PubMed     Abstract available
     
     
     
174. BRAILLON A
     Registry-based safety studies of migraine drugs in pregnancy: Acknowledging our failures.
     Cephalalgia. 2024;44:3331024241262486.
     PubMed    
     
     
     
175. 
     Corrigendum to "Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials".
     Cephalalgia. 2024;44:3331024241255216.
     PubMed    
     
     
     
176. 
     Corrigendum to: Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
     Cephalalgia. 2024;44:3331024241254952.
     PubMed    
     
     
     May 2024
177. RASMUSSEN AV, Jensen RH, Gantenbein A, Sumelahti ML, et al
     Consensus recommendations on the role of nurses in headache care: A European e-Delphi study.
     Cephalalgia. 2024;44:3331024241252161.
     PubMed     Abstract available
     
     
     
178. KOKOTI L, Al-Karagholi MA, Zhuang ZA, Amirguliyev S, et al
     Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: A randomized clinical trial.
     Cephalalgia. 2024;44:3331024241248211.
     PubMed     Abstract available
     
     
     
179. AKGOR U, Ince O
     Comment on ''Correlation between endometriosis and migraine features: Results from a prospective case-control study''.
     Cephalalgia. 2024;44:3331024241254824.
     PubMed    
     
     
     
180. GIRI S, Tronvik E, Dalen H, Ellekjaer H, et al
     Migraine and risk of atrial fibrillation: A 9-year follow-up based on the Trondelag Health Study.
     Cephalalgia. 2024;44:3331024241254517.
     PubMed     Abstract available
     
     
     
181. AL-HASSANY L, Boucherie DM, Couturier EGM, MaassenVanDenBrink A, et al
     Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
     Cephalalgia. 2024;44:3331024241248837.
     PubMed     Abstract available
     
     
     April 2024
182. RATTANAWONG W, Rapoport A, Srikiatkhachorn A
     Medication "underuse" headache.
     Cephalalgia. 2024;44:3331024241245658.
     PubMed     Abstract available
     
     
     
183. MITTER VR, Lupattelli A, Bjork MH, Nordeng HME, et al
     Identification and characterization of migraine in pregnancy: A Norwegian registry-based cohort study.
     Cephalalgia. 2024;44:3331024241248846.
     PubMed     Abstract available
     
     
     
184. GARCIA-AZORIN D, Martinez-Badillo C, Camina Muniz J, Gago-Veiga AB, et al
     CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.
     Cephalalgia. 2024;44:3331024241248833.
     PubMed     Abstract available
     
     
     
185. WHITAKER DJ, Dumkrieger GM, Hentz JG, Dodick DW, et al
     Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine.
     Cephalalgia. 2024;44:3331024241249747.
     PubMed     Abstract available
     
     
     
186. CROOP R, Berman G, Kudrow D, Mullin K, et al
     A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
     Cephalalgia. 2024;44:3331024241232944.
     PubMed     Abstract available
     
     
     
187. OLFAT M, Hosseinpour S, Masoumi S, Gogia Rastogi R, et al
     A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: a randomized double-blind clinical trial.
     Cephalalgia. 2024;44:3331024241230963.
     PubMed     Abstract available
     
     
     March 2024
188. PASCUAL-MATO M, Garate G, de Prado-Tejerina C, Garcia MJ, et al
     Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study.
     Cephalalgia. 2024;44:3331024241233979.
     PubMed     Abstract available
     
     
     
189. SELNTIGIA A, Exacoustos C, Ortoleva C, Russo C, et al
     Correlation between endometriosis and migraine features: Results from a prospective case-control study.
     Cephalalgia. 2024;44:3331024241235210.
     PubMed     Abstract available
     
     
     
190. PORRECA F, Navratilova E, Hirman J, van den Brink AM, et al
     Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
     Cephalalgia. 2024;44:3331024241238153.
     PubMed     Abstract available
     
     
     
191. THOMSEN AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, et al
     Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura.
     Cephalalgia. 2024;44:3331024241237247.
     PubMed     Abstract available
     
     
     
192. LAMAS PEREZ R, Millan-Vazquez M, Gonzalez-Oria C
     Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study.
     Cephalalgia. 2024;44:3331024231226181.
     PubMed     Abstract available
     
     
     
193. SACCO S, Porreca F
     Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men.
     Cephalalgia. 2024;44:3331024241238157.
     PubMed    
     
     
     
194. DIENER HC, May A
     New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication.
     Cephalalgia. 2024;44:3331024241228605.
     PubMed     Abstract available
     
     
     
195. ASHINA H, Diener HC, Tassorelli C, Scher AI, et al
     Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury.
     Cephalalgia. 2024;44:3331024241234068.
     PubMed     Abstract available
     
     
     February 2024
196. TORRES-FERRUS M, Gallardo VJ, Alpuente A, Caronna E, et al
     Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
     Cephalalgia. 2024;44:3331024231222923.
     PubMed     Abstract available
     
     
     
197. THURAIAIYAH J, Ashina H, Christensen RH, Al-Khazali HM, et al
     Premonitory symptoms in migraine: A REFORM Study.
     Cephalalgia. 2024;44:3331024231223979.
     PubMed     Abstract available
     
     
     
198. PHILLIPS K, Clerkin-Oliver C, Nirantharakumar K, Crowe FL, et al
     How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis.
     Cephalalgia. 2024;44:3331024241229410.
     PubMed     Abstract available
     
     
     
199. VIANA M, Hougaard A, Tronvik E, Winnberg IG, et al
     Visual migraine aura iconography: A multicentre, cross-sectional study of individuals with migraine with aura.
     Cephalalgia. 2024;44:3331024241234809.
     PubMed     Abstract available
     
     
     
200. IKUMI N, Marti-Marca A, Torre-Sune A, Cerda-Company X, et al
     Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study.
     Cephalalgia. 2024;44:3331024241230279.
     PubMed     Abstract available
     
     
     
201. TASSORELLI C, Onishchenko K, Halker Singh RB, Duan M, et al
     Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
     Cephalalgia. 2024;44:3331024241235156.
     PubMed     Abstract available
     
     
     
202. SHEWALE AR, Brandenburg JA, Burslem K, Lipton RB, et al
     Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
     Cephalalgia. 2024;44:3331024241235139.
     PubMed     Abstract available
     
     
     January 2024
203. COPPOLA G, Renzo AD, Parisi V, Serrao M, et al
     Comment on "Lack of reproducibility of resting-state functional MRI findings in migraine with aura".
     Cephalalgia. 2024;44:3331024231225186.
     PubMed    
     
     
     
204. PICO MJ, Badri M, Michalak N, Siefferman JW, et al
     Systemic allergic reaction to galcanezumab (emgality): a case report.
     Cephalalgia. 2024;44:3331024231222914.
     PubMed     Abstract available
     
     
     
205. NIDDAM DM, Lai KL, Hsiao YT, Wang YF, et al
     Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.
     Cephalalgia. 2024;44:3331024231222637.
     PubMed     Abstract available
     
     
     
206. BUGGE NS, Grotta Vetvik K, Alstadhaug KB, Braaten T, et al
     Cumulative exposure to estrogen may increase the risk of migraine in women.
     Cephalalgia. 2024;44:3331024231225972.
     PubMed     Abstract available
     
     
     
207. FLORESCU AM, Lannov LV, Younis S, Cullum CK, et al
     No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
     Cephalalgia. 2024;44:3331024231222915.
     PubMed     Abstract available
     
     
     
208. RAHMAN SM, Luebke AE
     Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models.
     Cephalalgia. 2024;44:3331024231223971.
     PubMed     Abstract available
     
     
     
209. RAFFAELLI B, Do TP, Chaudhry BA, Amin FM, et al
     Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial.
     Cephalalgia. 2024;44:3331024231222916.
     PubMed     Abstract available
     
     
     
210. MONTE G, Papetti L, Ursitti F, Sforza G, et al
     Childhood primary stabbing headache: A double center study.
     Cephalalgia. 2024;44:3331024231225974.
     PubMed     Abstract available
     
     
     
211. KRISTOFFERSEN ES, Pallesen S, Waage S, Bjorvatn B, et al
     The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study.
     Cephalalgia. 2024;44:3331024231226323.
     PubMed     Abstract available
     
     
     December 2023
212. BASEDAU H, Ornello R, Matteis E, Davaasuren B, et al
     Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?
     Cephalalgia. 2023;43:3331024231218392.
     PubMed     Abstract available
     
     
     
213. PENSATO U, Cevoli S, Pierangeli G, Cortelli P, et al
     The evolutionary meaning of migraine.
     Cephalalgia. 2023;43:3331024231209303.
     PubMed     Abstract available
     
     
     
214. TEZUKA T, Shibata M, Hanaoka H, Izawa Y, et al
     Systemic lupus erythematosus mimicking retinal migraine: a case report.
     Cephalalgia. 2023;43:3331024231219477.
     PubMed     Abstract available
     
     
     
215. DOBOS D, Kokonyei G, Gyebnar G, Szabo E, et al
     Microstructural differences in migraine: A diffusion-tensor imaging study.
     Cephalalgia. 2023;43:3331024231216456.
     PubMed     Abstract available
     
     
     
216. AL-KARAGHOLI MA
     Targeting CGRP pathways and aura: A peripheral site with a central effect.
     Cephalalgia. 2023;43:3331024231212895.
     PubMed     Abstract available
     
     
     
217. CHRISTOPHERSEN P, Dyhring T
     The shortcoming of using glibenclamide in exploratory clinical headache provocation studies.
     Cephalalgia. 2023;43:3331024231219475.
     PubMed     Abstract available
     
     
     November 2023
218. VAN DER AREND B, Terwindt GM
     Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days".
     Cephalalgia. 2023;43:3331024231208123.
     PubMed    
     
     
     
219. DAUNGSUPAWONG H, Wiwanitkit V
     Comment on "Effect of COVID vaccination on monthly migraine days".
     Cephalalgia. 2023;43:3331024231208121.
     PubMed    
     
     
     
220. AL-KHAZALI HM, Christensen RH, Dodick DW, Chaudhry BA, et al
     Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache.
     Cephalalgia. 2023;43:3331024231210930.
     PubMed     Abstract available
     
     
     
221. NAVARRO-PEREZ MP, Santos-Lasaosa S, Olesen J
     Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal.
     Cephalalgia. 2023;43:3331024231202243.
     PubMed     Abstract available
     
     
     
222. HOUGAARD A, Gaist D, Garde E, Iversen P, et al
     Lack of reproducibility of resting-state functional MRI findings in migraine with aura.
     Cephalalgia. 2023;43:3331024231212574.
     PubMed     Abstract available
     
     
     
223. BAHRA A
     Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment.
     Cephalalgia. 2023;43:3331024231214239.
     PubMed     Abstract available
     
     
     
224. GARCIA-AZORIN D, Santana-Lopez L, Lozano-Alonso JE, Ordax-Diez A, et al
     InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection.
     Cephalalgia. 2023;43:3331024231212900.
     PubMed     Abstract available
     
     
     
225. ASHINA M, Mitsikostas DD, Amin FM, Kokturk P, et al
     Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
     Cephalalgia. 2023;43:3331024231214987.
     PubMed     Abstract available
     
     
     October 2023
226. SEBASTIANELLI G, Casillo F, Abagnale C, Renzo AD, et al
     Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition.
     Cephalalgia. 2023;43:3331024231202240.
     PubMed     Abstract available
     
     
     
227. AL-KHAZALI HM, Ashina H, Christensen RH, Wiggers A, et al
     An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study.
     Cephalalgia. 2023;43:3331024231206375.
     PubMed     Abstract available
     
     
     
228. DEV P, Favas TT, Jaiswal R, Cyriac M, et al
     The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial.
     Cephalalgia. 2023;43:3331024231182684.
     PubMed     Abstract available
     
     
     
229. CHUANG CH, Li JY, King JT, Chen WT, et al
     Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study.
     Cephalalgia. 2023;43:3331024231206781.
     PubMed     Abstract available
     
     
     
230. CHRISTENSEN RH, Eigenbrodt AK, Ashina H, Steiner TJ, et al
     What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies.
     Cephalalgia. 2023;43:3331024231206376.
     PubMed     Abstract available
     
     
     
231. KUAN AS, Chen SP, Wang YF, Wang SJ, et al
     Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
     Cephalalgia. 2023;43:3331024231208110.
     PubMed     Abstract available
     
     
     
232. ZLOOF Y, Tsur AM, Simchoni M, Derazne E, et al
     Body mass index and migraine in adolescence: A nationwide study.
     Cephalalgia. 2023;43:3331024231209309.
     PubMed     Abstract available
     
     
     
233. ALEKSOVSKA K, Hershey AD, Deen M, Icco R, et al
     Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
     Cephalalgia. 2023;43:3331024231206162.
     PubMed     Abstract available
     
     
     
234. BELIN AC, Barloese MC
     The genetics and chronobiology of cluster headache.
     Cephalalgia. 2023;43:3331024231208126.
     PubMed     Abstract available
     
     
     September 2023
235. VAN DER AREND BWH, Bloemhof MM, van der Schoor AG, van Zwet EW, et al
     Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study.
     Cephalalgia. 2023;43:3331024231198792.
     PubMed     Abstract available
     
     
     August 2023
236. ALPUENTE A, Torre-Sune A, Caronna E, Gine-Cipres E, et al
     Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
     Cephalalgia. 2023;43:3331024231177636.
     PubMed     Abstract available
     
     
     
237. LA ROCCA M, Laporta A, Clemente L, Ammendola E, et al
     Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
     Cephalalgia. 2023;43:3331024231189751.
     PubMed     Abstract available
     
     
     
238. ADAM I, Elmugabil A, AlHabardi N
     History of maternal migraine and its association with preeclampsia: A case-control study in a low-resource setting in Sudan, Africa.
     Cephalalgia. 2023;43:3000605231193823.
     PubMed     Abstract available
     
     
     
239. PULEDDA F, Vigano A, Sebastianelli G, Parisi V, et al
     Electrophysiological findings in migraine may reflect abnormal synaptic plasticity mechanisms: A narrative review.
     Cephalalgia. 2023;43:3331024231195780.
     PubMed     Abstract available
     
     
     
240. LIPTON RB, Halker Singh RB, Mechtler L, McVige J, et al
     Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
     Cephalalgia. 2023;51:3331024231190296.
     PubMed     Abstract available
     
     
     July 2023
241. PATTERSON GENTILE C, Aguirre GK, Hershey AD, Szperka CL, et al
     Symptoms associated with headache in youth.
     Cephalalgia. 2023;43:3331024231187162.
     PubMed     Abstract available
     
     
     June 2023
242. VERHAGEN IE, van der Arend BW, van Casteren DS, Thiermann NJ, et al
     Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.
     Cephalalgia. 2023;43:3331024231164322.
     PubMed     Abstract available
     
     
     
243. PELZER N, de Boer I, van den Maagdenberg AMJM, Terwindt GM, et al
     Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives.
     Cephalalgia. 2023;43:3331024231180564.
     PubMed     Abstract available
     
     
     
244. KLAN T, Gaul C, Liesering-Latta E, Witthoft M, et al
     Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial.
     Cephalalgia. 2023;43:3331024231178237.
     PubMed     Abstract available
     
     
     
245. BERTZ R, Bhardwaj R, Morris BA, Ashbrenner E, et al
     A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
     Cephalalgia. 2023;43:3331024231179131.
     PubMed     Abstract available
     
     
     
246. BUTURE A, Tomkins EM, Shukralla A, Troy E, et al
     Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the
     Cephalalgia. 2023;43:3331024231182126.
     PubMed     Abstract available
     
     
     
247. ADAMS AM, Buse DC, Leroux E, Lanteri-Minet M, et al
     Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.
     Cephalalgia. 2023;43:3331024231180611.
     PubMed     Abstract available
     
     
     
248. CARCEL C, Haghdoost F, Shen J, Nanda P, et al
     The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231183166.
     PubMed     Abstract available
     
     
     
249. THOMSEN AV, Puonti O, Gaist D, Kyvik KO, et al
     Investigations of the subarachnoid space as a potential link between aura and headache in migraine: A case-control MRI study.
     Cephalalgia. 2023;43:3331024231170541.
     PubMed     Abstract available
     
     
     
250. CONSTANTINIDIS TS, Arvaniti C, Fakas N, Rudolf J, et al
     The prevalence and burden of medication overuse headache in Greece.
     Cephalalgia. 2023;43:3331024231184909.
     PubMed     Abstract available
     
     
     May 2023
251. VAN DER AREND BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, et al
     Defining migraine days, based on longitudinal E-diary data.
     Cephalalgia. 2023;43:3331024231166625.
     PubMed     Abstract available
     
     
     
252. CHEEMA S, Mehta D, Ray JC, Hutton EJ, et al
     New daily persistent headache: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231168089.
     PubMed     Abstract available
     
     
     
253. STUBBERUD A, Ingvaldsen SH, Brenner E, Winnberg I, et al
     Forecasting migraine with machine learning based on mobile phone diary and wearable data.
     Cephalalgia. 2023;43:3331024231169244.
     PubMed     Abstract available
     
     
     
254. ASHINA M, Lanteri-Minet M, Ettrup A, Christoffersen CL, et al
     Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
     Cephalalgia. 2023;43:3331024231170807.
     PubMed     Abstract available
     
     
     
255. VAN WELIE RF, van Welie FC, de Vries Lentsch S, Dahan A, et al
     Characterizing opioid use in a Dutch cohort with migraine.
     Cephalalgia. 2023;43:3331024231174160.
     PubMed     Abstract available
     
     
     
256. HSIAO FJ, Chen WT, Wang YF, Chen SP, et al
     Identification of patients with chronic migraine by using sensory-evoked oscillations from the electroencephalogram classifier.
     Cephalalgia. 2023;43:3331024231176074.
     PubMed     Abstract available
     
     
     
257. GULDIKEN YC, Petropoulos IN, Malik A, Malik RA, et al
     Corneal confocal microscopy identifies corneal nerve fiber loss in patients with migraine.
     Cephalalgia. 2023;43:3331024231170810.
     PubMed     Abstract available
     
     
     
258. RUSCHEWEYH R, Dresler T, Forderreuther S, Gaul C, et al
     What do patients' efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry.
     Cephalalgia. 2023;43:3331024231174855.
     PubMed     Abstract available
     
     
     
259. STEINER TJ
     Classification of migraine and tension-type headache: A response to the proposals of Olesen.
     Cephalalgia. 2023;43:3331024231169240.
     PubMed    
     
     
     
260. SUZUKI K, Suzuki S, Shiina T, Tatsumoto M, et al
     Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
     Cephalalgia. 2023;43:3331024231177649.
     PubMed     Abstract available
     
     
     
261. PARK CG, Na HY, Park DE, Kim HY, et al
     Altered interictal serum histamine and immunoglobulin E but unchanged tryptase levels in individuals with episodic and chronic migraine.
     Cephalalgia. 2023;43:3331024231178218.
     PubMed     Abstract available
     
     
     
262. ABU-ARAFEH I, Hershey AD, Diener HC, Tassorelli C, et al
     Guidelines Update: Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition - An experience-based update.
     Cephalalgia. 2023;43:3331024231178239.
     PubMed     Abstract available
     
     
     April 2023
263. GIRI S, Tronvik E, Linde M, Pedersen SA, et al
     Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
     Cephalalgia. 2023;43:3331024231156922.
     PubMed     Abstract available
     
     
     
264. OLESEN J, Jensen RH
     The Global Campaign Against Headache and its future relation to IHS and WHO.
     Cephalalgia. 2023;43:3331024231159625.
     PubMed     Abstract available
     
     
     
265. HAGHDOOST F, Puledda F, Garcia-Azorin D, Huessler EM, et al
     Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
     Cephalalgia. 2023;43:3331024231159366.
     PubMed     Abstract available
     
     
     
266. NIDDAM DM, Wu SW, Lai KL, Yang YY, et al
     An altered reward system characterizes chronic migraine with medication overuse headache.
     Cephalalgia. 2023;43:3331024231158088.
     PubMed     Abstract available
     
     
     
267. ASAWAVICHIENJINDA T, Sathitratanacheewin S, Chokesuwattanaskul R
     "Wearing-off" efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials.
     Cephalalgia. 2023;43:3331024231161261.
     PubMed     Abstract available
     
     
     
268. IANNONE LF, Burgalassi A, Vigani G, Tabasso G, et al
     Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
     Cephalalgia. 2023;43:3331024231160519.
     PubMed     Abstract available
     
     
     
269. FAVONI V, Mascarella D, Giannini G, Bauleo S, et al
     Prevalence, natural history and dynamic nature of chronic headache and medication overuse headache in Italy: The SPARTACUS study.
     Cephalalgia. 2023;43:3331024231157677.
     PubMed     Abstract available
     
     
     
270. ASHINA M, Roos C, Li LQ, Komori M, et al
     Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
     Cephalalgia. 2023;43:3331024231161745.
     PubMed     Abstract available
     
     
     
271. ZHANG L, Zhou Y, Wang Y, Yang L, et al
     Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model.
     Cephalalgia. 2023;43:3331024231163131.
     PubMed     Abstract available
     
     
     
272. RUSSO CV, Sacca F, Braca S, Sansone M, et al
     Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study.
     Cephalalgia. 2023;43:3331024231161809.
     PubMed     Abstract available
     
     
     
273. OLESEN J
     Classification of migraine and tension-type headache.
     Cephalalgia. 2023;43:3331024221139238.
     PubMed    
     
     
     
274. CROWE HM, Wesselink AK, Hatch EE, Wise LA, et al
     Migraine and risk of hypertensive disorders of pregnancy: A population-based cohort study.
     Cephalalgia. 2023;43:3331024231161746.
     PubMed     Abstract available
     
     
     
275. SAKAI F, Igarashi H, Yokoyama M, Begasse de Dhaem O, et al
     Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees.
     Cephalalgia. 2023;43:3331024231165682.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.